Sarcopenia is prevalent in patients with Crohn's disease in clinical remission
✍ Scribed by Stéphane M. Schneider; Rima Al-Jaouni; Jerôme Filippi; Jean-Baptiste Wiroth; Gilbert Zeanandin; Kamel Arab; Xavier Hébuterne
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 201 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
✦ Synopsis
Background:
Patients with Crohn's disease (CD) are prone to osteoporosis. A loss of muscle mass, called sarcopenia, is responsible for an increased risk of disability. Many factors associated with osteopenia also decrease muscle mass. The aim of the present study was to measure the prevalence of sarcopenia in CD patients in remission and uncover its relationship with osteopenia.
Methods:
In all, 82 CD patients (43 female / 39 male; 36 Ϯ 14 years; body mass index [BMI] 21.1 Ϯ 3.4) and 50 healthy volunteers (30F/20M; 39 Ϯ 13 years; BMI 22.2 Ϯ 2.5) were studied. Body composition was assessed using dual-energy x-ray absorptiometry. Sarcopenia was defined as an appendicular skeletal muscle index (ASMI) below 5.45 kg/m 2 for women and 7.26 for men. Osteopenia was defined as a T-score for bone mineral density (BMD) (g/cm 2 ) below Ϫ1.0.
Results:
In all, 60% of CD patients were found to be sarcopenic and 30% osteopenic, compared to 16% and 4% of controls, respectively (P Ͻ 0.01). ASMI was significantly lower in patients than in controls (6.0 Ϯ 1.1 versus 6.5 Ϯ 1.2; P Ͻ 0.05). Sarcopenic patients had significantly (P Ͻ 0.01) lower BMI (20.0 Ϯ 3.5 versus 22.7 Ϯ 2.8 kg/m 2 ), lean mass (41.5 Ϯ 9.1 versus 48.1 Ϯ 9.1 kg), and BMD (1.09 Ϯ 0.12 versus 1.15 Ϯ 0.08 g/cm 2 ) than nonsarcopenic patients; 91% of sarcopenic patients were also osteopenic. ASMI correlated with BMD (r ϭ 0.46; P Ͻ 0.01) and BMI (r ϭ 0.38; P Ͻ 0.01).
Conclusions:
The prevalence of sarcopenia is high in young CD patients and strongly related to osteopenia. These 2 phenomena may share similar mechanisms. Simultaneous screening for sarcopenia and osteopenia may be useful in CD patients.
📜 SIMILAR VOLUMES
Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr
## Background: Patients with longstanding quiescent crohn's disease on azathioprine usually maintain an excellent quality of life but are also concerned about long-term safety. this may affect adherence to treatment. the aim of the present study was to assess the adherence to azathioprine in a coho
Background: Patients with inflammatory bowel disease (IBD) have an increased risk of thromboembolic complications. The pathogenesis of IBD is not really clear and a high thrombin activity might contribute to the pathogenesis. We measured thrombin generation by means of calibrated automated thrombogr